Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
alloantibody
clinical research/practice
crossmatch
desensitization
immunosuppressant - other
immunosuppression/immune modulation
kidney transplantation/nephrology
sensitization
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
11
06
2021
received:
21
03
2021
accepted:
04
07
2021
pubmed:
9
7
2021
medline:
1
2
2022
entrez:
8
7
2021
Statut:
ppublish
Résumé
Imlifidase is a cysteine proteinase which specifically cleaves IgG, inhibiting Fc-mediated effector function within hours of administration. Imlifidase converts a positive crossmatch to a potential donor (T cell, B cell, or both), to negative, enabling transplantation to occur between previously HLA incompatible donor-recipient pairs. To date, 39 crossmatch positive patients received imlifidase prior to a kidney transplant in four single-arm, open-label, phase 2 studies. At 3 years, for patients who were AMR+ compared to AMR-, death-censored allograft survival was 93% vs 77%, patient survival was 85% vs 94%, and mean eGFR was 49 ml/min/1.73 m
Identifiants
pubmed: 34236770
doi: 10.1111/ajt.16754
pmc: PMC9290474
pii: S1600-6135(22)08838-4
doi:
Substances chimiques
HLA Antigens
0
Banques de données
ClinicalTrials.gov
['NCT02790437']
EudraCT
['2016-002064-13']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3907-3918Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Transplantation. 2013 Mar 27;95(6):852-8
pubmed: 23511212
Transpl Immunol. 2011 Apr 15;24(3):164-71
pubmed: 21185937
N Engl J Med. 2017 Aug 3;377(5):442-453
pubmed: 28767349
Ann Surg. 2018 Sep;268(3):488-496
pubmed: 30004918
Am J Transplant. 2018 Nov;18(11):2752-2762
pubmed: 29561066
Transplantation. 2019 Aug;103(8):1574-1581
pubmed: 31283678
Am J Transplant. 2012 Jun;12(6):1469-78
pubmed: 22390272
Am J Transplant. 2018 Aug;18(8):1924-1935
pubmed: 29734498
Kidney Int. 2015 Feb;87(2):409-16
pubmed: 25054778
Am J Transplant. 2021 Dec;21(12):3907-3918
pubmed: 34236770
Am J Transplant. 2020 Aug;20(8):2101-2112
pubmed: 32065704
Clin Transplant. 2019 Dec;33(12):e13751
pubmed: 31769104
N Engl J Med. 2016 Mar 10;374(10):940-50
pubmed: 26962729
J Am Soc Nephrol. 2016 Sep;27(9):2833-41
pubmed: 26888475
Transplantation. 2020 Jul;104(7):1483-1490
pubmed: 31568212
Transplantation. 2021 Aug 1;105(8):1808-1817
pubmed: 33093408
Transplantation. 2020 Aug;104(8):1574-1579
pubmed: 32732834
Hum Immunol. 2017 Jan;78(1):37-40
pubmed: 27771384
Transplantation. 2003 Apr 27;75(8):1291-5
pubmed: 12717218
Am J Transplant. 2004 Oct;4(10):1662-8
pubmed: 15367222
Am J Transplant. 2016 Jun;16(6):1834-47
pubmed: 26932731
Am J Transplant. 2019 Oct;19(10):2926-2933
pubmed: 31155833
Am J Transplant. 2019 Apr;19(4):1129-1138
pubmed: 30372592
Am J Kidney Dis. 2011 Mar;57(3):466-75
pubmed: 21257243
Transplantation. 2020 Jul;104(7):1456-1461
pubmed: 31577673